139 related articles for article (PubMed ID: 31038235)
1. Identification of potentially druggable molecular alterations in skin adnexal malignancies.
Cavalieri S; Busico A; Capone I; Conca E; Dallera E; Quattrone P; Licitra L; Pruneri G; Bossi P; Perrone F
J Dermatol; 2019 Jun; 46(6):507-514. PubMed ID: 31038235
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
3. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
4. NGS Analysis Confirms Common
Peterson C; Moore R; Hicks JL; Morsberger LA; De Marzo AM; Zou Y; Eberhart CG; Campbell AA
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445161
[TBL] [Abstract][Full Text] [Related]
5. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
6. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
Dias-Santagata D; Lam Q; Bergethon K; Baker GM; Iafrate AJ; Rakheja D; Hoang MP
Mod Pathol; 2011 Jul; 24(7):974-82. PubMed ID: 21423156
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.
Chan MP; Plouffe KR; Liu CJ; Palanisamy N; Carskadon S; Zhao L; Nazarian RM; Durham AB; Johnson TM; Andea AA; Patel RM; Lowe L; Fullen DR; Brown NA; Tomlins SA; Udager AM; Harms PW
Mod Pathol; 2020 Jun; 33(6):1092-1103. PubMed ID: 31857679
[TBL] [Abstract][Full Text] [Related]
10. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
11. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathology of skin adnexal tumours.
Plotzke JM; Adams DJ; Harms PW
Histopathology; 2022 Jan; 80(1):166-183. PubMed ID: 34197659
[TBL] [Abstract][Full Text] [Related]
14. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
15. Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.
Harvey NT; Tabone T; Erber W; Wood BA
Pathology; 2016 Aug; 48(5):454-62. PubMed ID: 27311873
[TBL] [Abstract][Full Text] [Related]
16. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
17. Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Akahane T; Kanomata N; Harada O; Yamashita T; Kurebayashi J; Tanimoto A; Moriya T
BMC Cancer; 2020 Oct; 20(1):944. PubMed ID: 33004031
[TBL] [Abstract][Full Text] [Related]
18. Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.
Ye Q; Qi F; Bian L; Zhang SH; Wang T; Jiang ZF
Chin Med J (Engl); 2017 Mar; 130(5):522-529. PubMed ID: 28229982
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutation in sebaceous neoplasms.
Muñoz-Jiménez MT; Blanco L; Ruano Y; Carrillo R; Santos-Briz Á; Riveiro-Falkenbach E; Requena L; Kutzner H; Garrido MC; Rodríguez-Peralto JL
Virchows Arch; 2021 Sep; 479(3):551-558. PubMed ID: 33768319
[TBL] [Abstract][Full Text] [Related]
20. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
